About 19 results found for searched term "JAK-IN-10" (0.132 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41706 | JAK1-IN-10 | JAK |
| JAK1-IN-10, a cyano-substituted cyclic hydrazine derivative, is a potent and selective JAK1 inhibitor. | ||
| M49596 | JAK-IN-10 | JAK |
| JAK-IN-10 is a JAK inhibitor. | ||
| M11227 | FM-479 | JAK |
| Fm-479 was a negative control of FM-381 and showed no activity against JAK3 or other kinases. Fm-381 is a potent covalent reversible inhibitor of JAK3 targeting unique Cys909. For JAK3, FM-381 was 410, 2700 and 3600 times more selective than JAK1, JAK2 and TYK2 with IC50 of 127 pM. | ||
| M4912 | GLPG0634 analogue | JAK |
| GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. | ||
| M5315 | Baricitinib phosphate | JAK |
| INCB028050; LY3009104 | ||
| Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. | ||
| M5827 | Oclacitinib maleate | JAK |
| PF-03394197 | ||
| Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases. | ||
| M6308 | Ritlecitinib | JAK |
| PF-06651600 | ||
| Ritlecitinib (PF-06651600) is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2. | ||
| M10698 | FM-381 | JAK |
| FM-381 is a potent, covalent, reversible JAK3 inhibitor that targets the Cys909 site. FM-381 for JAK3 IC50 The value is 127 pM, which is 410, 2700, and 3600 times more selective than JAK1, JAK2, and TYK2, respectively. | ||
| M17579 | Brevilin A | Sesquiterpenoids |
| Brevilin A is an orally active STAT3/JAK inhibitor, with IC50 of 10.6 μM against STAT3. | ||
| M27897 | SD-1029 | JAK |
| SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation. | ||
| M28058 | MS-1020 | JAK |
| MS-1020 is a potent and ATP-competitive JAK3 inhibitor. MS-1020 inhibits JAK3/STAT signaling and induces apoptosis. MS-1020 promotes cell death. MS-1020 decreases the expression of tyrosine phosphorylated STAT3 levels. MS-1020 has the potential for the research of cancers harboring aberrant JAK3 signaling. | ||
| M28457 | Ivarmacitinib | JAK |
| SHR0302 | ||
| Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects. | ||
| M28893 | JAK3-IN-1 | JAK |
| JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC50 of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC50 of 896 nM) and JAK2 (IC50 of 1050 nM). | ||
| M31205 | G5-7 | JAK |
| G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study. | ||
| M41705 | JAK-IN-25 | JAK |
| JAK-IN-25 is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. | ||
| M49594 | JAK3-IN-7 | JAK |
| JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. | ||
| M49603 | JAK-IN-21 | JAK |
| JAK-IN-21 is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively. | ||
| M49607 | JAK-IN-34 | JAK |
| JAK-IN-34 is a potent against of JAKs with IC50 values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively. | ||
| M49635 | ZM39923 | JAK |
| ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
